We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

109 hedge funds and large institutions have $662M invested in Amicus Therapeutics in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 46 increasing their positions, 17 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 17

136% more capital invested

Capital invested by funds: $280M → $662M (+$382M)

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

15% more funds holding

Funds holding: 95109 (+14)

6% more call options, than puts

Call options by funds: $6.98M | Put options by funds: $6.56M

Holders
109
Holders Change
+14
Holders Change %
+14.74%
% of All Funds
2.91%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.16%
New
35
Increased
46
Reduced
17
Closed
19
Calls
$6.98M
Puts
$6.56M
Net Calls
+$424K
Net Calls Change
-$1.24M
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
101
AllianceBernstein
Tennessee
$31K +$25.4K +3,700 New
PCM
102
Prelude Capital Management
New York
$29K -$13.7K -2,000 -36%
Teacher Retirement System of Texas
103
Teacher Retirement System of Texas
Texas
$19K +$15.5K +2,258 New
Creative Planning
104
Creative Planning
Kansas
$10K -$2.06K -300 -20%
Barclays
105
Barclays
United Kingdom
$6K +$3.86K +563 +399%
SFPIA
106
Stevens First Principles Investment Advisors
California
$3K -$686 -100 -20%
SM
107
Sabby Management
Florida
$2.05K +$1.69M +246,697 New
AA
108
AlphaMark Advisors
Kentucky
$1K
Manulife (Manufacturers Life Insurance)
109
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$20 +$14.2K +2,070 +590%
DM
110
Deerfield Management
New York
-$2.86M -480,000 Closed
ICRM
111
Insight Capital Research & Management
California
-$1.48M -248,383 Closed
Point72 Asset Management
112
Point72 Asset Management
Connecticut
-$1.17M -195,900 Closed
SIM
113
Spark Investment Management
New York
-$988K -166,400 Closed
JG
114
Jefferies Group
New York
-$595K -100,000 Closed
VKH
115
Virtu KCG Holdings
New York
-$352K -59,244 Closed
Jacobs Levy Equity Management
116
Jacobs Levy Equity Management
New Jersey
-$333K -55,885 Closed
BIP
117
Brandes Investment Partners
California
-$218K -36,700 Closed
NCCM
118
Nine Chapters Capital Management
New Jersey
-$198K -33,300 Closed
CSS
119
Cubist Systematic Strategies
Connecticut
-$170K -28,622 Closed
LP
120
LMR Partners
United Kingdom
-$163K -27,459 Closed
DTL
121
Dynamic Technology Lab
Singapore
-$136K -22,667 Closed
DCC
122
Dow Chemical Company
Michigan
-$132K -22,162 Closed
AL
123
Airain Ltd
Guernsey
-$124K -20,822 Closed
EMG
124
Ellington Management Group
Connecticut
-$90K -15,200 Closed
BJ
125
BlackRock Japan
Japan
-$30K -4,988 Closed

FOLD Hedge Fund Activity: Q4 2014 in Review

109 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2014, worth a combined $662M — up 136% from $280M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new FOLD positions and 19 closed out — a net gain of 16 holders — while 46 added to existing stakes and 17 trimmed.

The largest buyer was Sectoral Asset Management, adding an estimated $31.3M. The largest seller was Visium Asset Management, cutting an estimated $4.07M.

  • 109 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2014, up from 95 in Q3 2014.
  • Funds reported $662M of Amicus Therapeutics stock for Q4 2014, up 136% quarter-over-quarter.
  • 35 funds opened new Amicus Therapeutics positions in Q4 2014 and 19 closed out, a net change of +16 holders.
  • The largest Amicus Therapeutics buyer in Q4 2014 was Sectoral Asset Management, an estimated $31.3M added.
  • The largest Amicus Therapeutics seller in Q4 2014 was Visium Asset Management, an estimated $4.07M sold.

Based on aggregated 13F filings for Q4 2014.